Facebook
X
LinkedIn
ForwardMayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium 2026
This course offers Live (in-person) and Livestream (virtual) attendance options
November 13 - 14, 2026 - Wynn Las Vegas - Las Vegas, Nevada
Course Directors - Tanios S. Bekaii-Saab, M.D., Mitesh J. Borad, M.D., G. Dan Duda, D.M.D., Ph.D and Mark J. Truty, M.D., M.S.
The 2026 Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium will review multidisciplinary, stage-specific management of hepatobiliary and pancreatic cancers. It highlights advances in immunotherapy, targeted and biomarker-driven treatments, surgical and transplant strategies, and emerging technologies such as AI and liquid biopsy to optimize patient outcomes.
To see the course fee, please log in or create an account
| Registration Fee(s) | |
|---|---|
| M.D., D.O., Ph.D. | $875 |
| Residents, Physician Assistants and Nurse Practitioners | $750 |
| Livestream | $675 |
Target Audience
This course is intended for surgeons, gastroenterologists, medical and radiation oncologists, laboratory scientists, and allied health professionals in the following specialties: medical oncology, hematology, gastroenterology, radiation oncology, surgical oncology, pathology, radiology, and laboratory research science.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Evaluate current first-line and evolving systemic treatment strategies for advanced hepatocellular carcinoma (HCC), including anti-angiogenic/immunotherapy combinations, STRIDE, and dual checkpoint inhibition approaches.
- Apply stage-specific, multidisciplinary treatment strategies for hepatocellular carcinoma and cholangiocarcinoma, incorporating surgical, locoregional, and transplant-based approaches.
- Integrate precision oncology into hepatobiliary and pancreatic cancers by utilizing biomarkers (e.g., HER2, IDH1/2, FGFR) and liquid biopsy technologies to guide targeted therapy selection.
- Assess optimal management strategies for pancreatic adenocarcinoma across disease stages, including neoadjuvant/adjuvant sequencing, resectability criteria, and emerging RAS-targeted therapies.
- Develop evidence-based treatment plans for rare hepatic and pancreatic tumors, including fibrolamellar HCC, pancreatic neuroendocrine tumors (PNETs), and uncommon exocrine pancreatic malignancies.
- Analyze emerging technologies and population health strategies, including artificial intelligence for early cancer detection and national approaches to addressing biliary tract cancer burden.
Attendance at any Mayo Clinic course does not indicate or guarantee competence or proficiency in the skills, knowledge or performance of any care or procedure(s) which may be discussed or taught in this course.
Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium 2026 | ||
Wynn Hotel & Casino, Las Vegas, Nevada | ||
November 13-14, 2026 | ||
Day 1 | Friday, November 13, 2026 | |
7:30 AM | Breakfast, Registration and Exhibits | |
8:20 AM | Welcome Announcements | |
Liver Session I: Challenges and Controversies in Advanced HCC Moderator: G. Dan Duda, D.M.D., Ph.D., FAIMBE, FAAAS | ||
8:30 AM | Debate: Anti-angiogenic and Checkpoints Are the Preferred Options for Advanced HCC Ghassan K. Abou-Alfa, M.D., J.D., M.B.A., Ph.D. (hc) | |
8:40 AM | Debate: STRIDE Regimen Would Be the Preferred Option for Advanced HCC | |
8:50 AM | Debate: Sustained Doublet Checkpoint Inhibitors Is the Way Forward For Advanced HCC Anthony B. El-Khoueiry, M.D. | |
9:00 AM | Interactive Q&A Session Presenters | |
Liver Session II: Managing HCC Challenges Moderator: Amit K. Mathur, M.D. | ||
9:15 AM | Expanding Indications for Surgical Resection in Hepatocellular Carcinoma: What is the Evidence? Adam Yopp, M.D. | |
9:35 AM | Modern HCC Transplantation Indications/Criteria: Primer for Non-Transplant Surgeons Christopher J. Sonnenday, M.D., M.H.S. | |
9:55 AM | Fibrolamellar HCC: Surgical Management of Localized/Metastatic Disease Ching-Wei D. Tzeng, M.D. | |
10:10 AM | Systemic Therapies for Fibrolammellar HCC John Gordan, M.D., Ph.D. | |
10:25 AM | Interactive Q&A Session Presenters | |
10:40 AM | AM Break and Exhibits | |
Liver Session III: Multidisciplinary Tumor Board Moderator: Channa R. Jayasekera, M.D. (10:45 AM - 11:15 AM), Daniel H. Ahn, D.O. (11:15 AM - 11:45AM) | ||
11:00 AM | Treatment Strategies for "Early-Stage" HCC Panelists: Amit K. Mathur, M.D., Adam Yopp, M.D., Christopher J. Sonnenday, M.D., M.H.S., Ching-Wei D. Tzeng, M.D., Daniel A. Adamo, M.D., Yasamin Sharifzadeh-Moghaddam, M.D., and Richard G. Frimpong, M.D., John Gordan, M.D., Ph.D. | |
11:30 AM | Treatment Strategies for "Advanced" HCC Panelists: Amit K. Mathur, M.D., Adam Yopp, M.D., Christopher J. Sonnenday, M.D., M.H.S., Ching-Wei D. Tzeng, M.D., Daniel A. Adamo, M.D., Yasamin Sharifzadeh-Moghaddam, M.D., and Richard G. Frimpong, M.D., John Gordan, M.D., Ph.D. | |
12:00 PM | Lunch & Exhibits | |
12:00 PM | Optional Product Theater 1: Company 1 (no CME credit) Location: Montrachet | |
State of the Art HPB Lecture Moderator: Mark J. Truty, M.D., M.S. | ||
1:00 PM | Endoscopic Palliative and Therapeutic Bypass Procedures in HPB Oncology: What is Now Possible Ryan J. Law, D.O. | |
1:30 PM | Interactive Q&A Session Presenters | |
Biliary Session I: Precision Oncology for Advanced Disease Moderator: Mitesh J. Borad, M.D. | ||
1:40 PM | Precision Medicine Advances in HCC – The Next Frontier? Nguyen H. Tran, M.D. | |
1:55 PM | Choosing Between HER2 Targeted Therapies in Biliary Tract Malignancies Milind M. Javle, M.D. | |
2:05 PM | IDH1/IDH2 and Emerging Opportunities in Biliary Tract Cancers Caitlin B. Conboy, M.D., Ph.D. | |
2:15 PM | Applications of Liquid Biopsy Technologies in the Management of Hepatobiliary Cancers Umair Majeed, M.B.B.S., M.D. | |
2:25 PM | FGFR Inhibitors – Where Have We Been and Where Are We Going? Daniel H. Ahn, D.O. | |
2:35 PM | Interactive Q&A Session Presenters | |
2:50 PM | PM Break and Exhibits | |
Biliary Session II: Challenges and Controversies in Localized Disease Moderator: Zhi Ven Fong, M.D., Dr.PH. | ||
3:10 PM | Incidental Gallbladder Cancer: Now What? Mark J. Truty, M.D., M.S. | |
3:25 PM | Transplant in Cholangiocarcinoma – Current and Evolving Indications Bashar A. Aqel, M.D. | |
3:40 PM | National Strategic Approach to Managing the Gallbladder Cancer Epidemic in Chile Jorge Gallardo, M.D. | |
3:55 PM | Is Adjuvant Therapy Appropriate for all Resected BTC Patients? TBC | |
4:10 PM | Interactive Q&A Session Presenters | |
Biliary Session III: Multidisciplinary Tumor Board Moderator: Daniel H. Ahn, D.O. | ||
4:25 PM | Localized Intrahepatic CCA Panelists: Zhi Ven Fong, M.D., Dr.PH., Bashar A. Aqel, M.D., Jorge Gallardo, M.D., TBC, Adam Yopp, M.D., Christopher J. Sonnenday, M.D., M.H.S., Amit K. Mathur, M.D., Daniel A. Adamo, M.D., Yasamin Sharifzadeh-Moghaddam, M.D., and Richard G. Frimpong, M.D. | |
4:45 PM | Neoadjuvant Therapy for Intrahepatic CCA Panelists: Zhi Ven Fong, M.D., Dr.PH., Bashar A. Aqel, M.D., Jorge Gallardo, M.D., TBC, Adam Yopp, M.D., Christopher J. Sonnenday, M.D., M.H.S., Amit K. Mathur, M.D., Daniel A. Adamo, M.D., Yasamin Sharifzadeh-Moghaddam, M.D., and Richard G. Frimpong, M.D. | |
5:05 PM | Management of Peri-Hilar CCA Panelists: Zhi Ven Fong, M.D., Dr.PH., Bashar A. Aqel, M.D., Jorge Gallardo, M.D., TBC, Adam Yopp, M.D., Christopher J. Sonnenday, M.D., M.H.S., Amit K. Mathur, M.D., Daniel A. Adamo, M.D., Yasamin Sharifzadeh-Moghaddam, M.D., and Richard G. Frimpong, M.D. | |
5:25 PM | Interactive Q&A Session Presenters | |
5:35 PM | Closing Remarks and Adjourn | |
|
| |
Day 2 | Saturday, November 14, 2026 | |
7:15 AM | Breakfast & Exhibits | |
7:15 AM | Optional Product Theater: Company 2 (no CME credit) Location: Montrachet | |
8:20 AM | Welcome Announcements | |
Pancreas Session I: Precision Oncology in the Treatment of Pancreatic Adenocarcinoma Moderator: Tanios S. Bekaii-Saab, M.D. | ||
8:30 AM | "KRA"cking the RAS Code in PDAC Nilofer S. Azad, M.D., F.A.S.C.O. | |
8:45 AM | KRAS WT PDAC: Targets Galore | |
9:00 AM | Other Emerging Targets in PDAC | |
Pancreas Session II: Reimagining the Standard in Localized Pancreatic Cancer Moderator: Ryan M. Carr, M.D., Ph.D. | ||
9:20 AM | Next-Generation Trial Design in the Perioperative Management of Pancreatic Cancer | |
9:40 AM | The Role of PET in Staging and Response in Pancreatic Adenocarcinoma | |
10:00 AM | Interactive Q&A Session Presenters | |
10:15 AM | AM Break and Exhibits | |
Pancreas Session III: Advances in Neuroendocrine and Other Pancreatic Malignancies Moderator: Thor R. Halfdanarson, M.D. | ||
10:35 AM | Is Radiation Useful in Pancreatic Neuroendocrine Tumors? Krishan R. Jethwa, M.D., M.P.H. | |
10:50 AM | Surgical Management of Functioning and Non‑Functioning Pancreatic Neuroendocrine Tumors Alexandra Gangi, M.D. | |
11:10 AM | Neoadjuvant Therapy for PNET: CAP/TEM and Beyond | |
11:30 AM | De Novo PDAC vs Invasive-IPMN: Is There a Real Difference? Katherine Poruk, M.D. | |
11:50 AM | Interactive Q&A Session Presenters | |
Pancreas Session IV: Multidisciplinary Tumor Board Moderator: Katherin Poruk, M.D., and Thor R. Halfdanarson, M.D. | ||
12:05 PM | Localized PNET Panelists: Eileen M. O'Reilly, M.D., Bassel F. El-Reyes, M.D., Nilofer S. Azad, M.D., F.A.S.C.O., Ben George, M.B.B.S., M.D., Krishnan R. Jethwa, M.D., M.P.H., Alexandra Gangi, M.D., Mark J. Truty, M.D., M.S., and Daniel Adamo, M.D. | |
12:25 PM | High Risk Non-Metastatic PDAC Panelists: Eileen M. O'Reilly, M.D., Bassel F. El-Reyes, M.D., Nilofer S. Azad, M.D., F.A.S.C.O., Ben George, M.B.B.S., M.D., Krishnan R. Jethwa, M.D., M.P.H., Alexandra Gangi, M.D., Mark J. Truty, M.D., M.S., and Daniel Adamo, M.D. | |
12:45 PM | Recurrent/Metastatic PDAC/PNET Panelists: Eileen M. O'Reilly, M.D., Bassel F. El-Reyes, M.D., Nilofer S. Azad, M.D., F.A.S.C.O., Ben George, M.B.B.S., M.D., Krishnan R. Jethwa, M.D., M.P.H., Alexandra Gangi, M.D., Mark J. Truty, M.D., M.S., and Daniel Adamo, M.D. | |
1:05 PM | Interactive Q&A Session Presenters | |
1:20 PM | Closing Remarks and Adjourn | |
[AG1]Should this be 9:15am as Dr. Truty noted in email invitation?
Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium 2026 | ||
Wynn Hotel & Casino, Las Vegas, Nevada | ||
November 13-14, 2026 | ||
Day 1 | Friday, November 13, 2026 | |
7:30 AM | Breakfast, Registration and Exhibits | |
8:20 AM | Welcome Announcements | |
Liver Session I: Challenges and Controversies in Advanced HCC Moderator: G. Dan Duda, D.M.D., Ph.D., FAIMBE, FAAAS | ||
8:30 AM | Debate: Anti-angiogenic and Checkpoints Are the Preferred Options for Advanced HCC Ghassan K. Abou-Alfa, M.D., J.D., M.B.A., Ph.D. (hc) | |
8:40 AM | Debate: STRIDE Regimen Would Be the Preferred Option for Advanced HCC | |
8:50 AM | Debate: Sustained Doublet Checkpoint Inhibitors Is the Way Forward For Advanced HCC Anthony B. El-Khoueiry, M.D. | |
9:00 AM | Interactive Q&A Session Presenters | |
Liver Session II: Managing HCC Challenges Moderator: Amit K. Mathur, M.D. | ||
9:15 AM | Expanding Indications for Surgical Resection in Hepatocellular Carcinoma: What is the Evidence? Adam Yopp, M.D. | |
9:35 AM | Modern HCC Transplantation Indications/Criteria: Primer for Non-Transplant Surgeons[AG1] Christopher J. Sonnenday, M.D., M.H.S. | |
9:55 AM | Fibrolamellar HCC: Surgical Management of Localized/Metastatic Disease Ching-Wei D. Tzeng, M.D. | |
10:10 AM | Systemic Therapies for Fibrolammellar HCC John Gordan, M.D., Ph.D. | |
10:25 AM | Interactive Q&A Session Presenters | |
10:40 AM | AM Break and Exhibits | |
Liver Session III: Multidisciplinary Tumor Board Moderator: Channa R. Jayasekera, M.D. (10:45 AM - 11:15 AM), Daniel H. Ahn, D.O. (11:15 AM - 11:45AM) | ||
11:00 AM | Treatment Strategies for "Early-Stage" HCC Panelists: Amit K. Mathur, M.D., Adam Yopp, M.D., Christopher J. Sonnenday, M.D., M.H.S., Ching-Wei D. Tzeng, M.D., Daniel A. Adamo, M.D., Yasamin Sharifzadeh-Moghaddam, M.D., and Richard G. Frimpong, M.D., John Gordan, M.D., Ph.D. | |
11:30 AM | Treatment Strategies for "Advanced" HCC Panelists: Amit K. Mathur, M.D., Adam Yopp, M.D., Christopher J. Sonnenday, M.D., M.H.S., Ching-Wei D. Tzeng, M.D., Daniel A. Adamo, M.D., Yasamin Sharifzadeh-Moghaddam, M.D., and Richard G. Frimpong, M.D., John Gordan, M.D., Ph.D. | |
12:00 PM | Lunch & Exhibits | |
12:00 PM | Optional Product Theater 1: Company 1 (no CME credit) Location: Montrachet | |
State of the Art HPB Lecture Moderator: Mark J. Truty, M.D., M.S. | ||
1:00 PM | Endoscopic Palliative and Therapeutic Bypass Procedures in HPB Oncology: What is Now Possible Ryan J. Law, D.O. | |
1:30 PM | Interactive Q&A Session Presenters | |
Biliary Session I: Precision Oncology for Advanced Disease Moderator: Mitesh J. Borad, M.D. | ||
1:40 PM | Precision Medicine Advances in HCC – The Next Frontier? Nguyen H. Tran, M.D. | |
1:55 PM | Choosing Between HER2 Targeted Therapies in Biliary Tract Malignancies Milind M. Javle, M.D. | |
2:05 PM | IDH1/IDH2 and Emerging Opportunities in Biliary Tract Cancers Caitlin B. Conboy, M.D., Ph.D. | |
2:15 PM | Applications of Liquid Biopsy Technologies in the Management of Hepatobiliary Cancers Umair Majeed, M.B.B.S., M.D. | |
2:25 PM | FGFR Inhibitors – Where Have We Been and Where Are We Going? Daniel H. Ahn, D.O. | |
2:35 PM | Interactive Q&A Session Presenters | |
2:50 PM | PM Break and Exhibits | |
Biliary Session II: Challenges and Controversies in Localized Disease Moderator: Zhi Ven Fong, M.D., Dr.PH. | ||
3:10 PM | Incidental Gallbladder Cancer: Now What? Mark J. Truty, M.D., M.S. | |
3:25 PM | Transplant in Cholangiocarcinoma – Current and Evolving Indications Bashar A. Aqel, M.D. | |
3:40 PM | National Strategic Approach to Managing the Gallbladder Cancer Epidemic in Chile Jorge Gallardo, M.D. | |
3:55 PM | Is Adjuvant Therapy Appropriate for all Resected BTC Patients? TBC | |
4:10 PM | Interactive Q&A Session Presenters | |
Biliary Session III: Multidisciplinary Tumor Board Moderator: Daniel H. Ahn, D.O. | ||
4:25 PM | Localized Intrahepatic CCA Panelists: Zhi Ven Fong, M.D., Dr.PH., Bashar A. Aqel, M.D., Jorge Gallardo, M.D., TBC, Adam Yopp, M.D., Christopher J. Sonnenday, M.D., M.H.S., Amit K. Mathur, M.D., Daniel A. Adamo, M.D., Yasamin Sharifzadeh-Moghaddam, M.D., and Richard G. Frimpong, M.D. | |
4:45 PM | Neoadjuvant Therapy for Intrahepatic CCA Panelists: Zhi Ven Fong, M.D., Dr.PH., Bashar A. Aqel, M.D., Jorge Gallardo, M.D., TBC, Adam Yopp, M.D., Christopher J. Sonnenday, M.D., M.H.S., Amit K. Mathur, M.D., Daniel A. Adamo, M.D., Yasamin Sharifzadeh-Moghaddam, M.D., and Richard G. Frimpong, M.D. | |
5:05 PM | Management of Peri-Hilar CCA Panelists: Zhi Ven Fong, M.D., Dr.PH., Bashar A. Aqel, M.D., Jorge Gallardo, M.D., TBC, Adam Yopp, M.D., Christopher J. Sonnenday, M.D., M.H.S., Amit K. Mathur, M.D., Daniel A. Adamo, M.D., Yasamin Sharifzadeh-Moghaddam, M.D., and Richard G. Frimpong, M.D. | |
5:25 PM | Interactive Q&A Session Presenters | |
5:35 PM | Closing Remarks and Adjourn | |
|
| |
Day 2 | Saturday, November 14, 2026 | |
7:15 AM | Breakfast & Exhibits | |
7:15 AM | Optional Product Theater: Company 2 (no CME credit) Location: Montrachet | |
8:20 AM | Welcome Announcements | |
Pancreas Session I: Precision Oncology in the Treatment of Pancreatic Adenocarcinoma Moderator: Tanios S. Bekaii-Saab, M.D. | ||
8:30 AM | "KRA"cking the RAS Code in PDAC Nilofer S. Azad, M.D., F.A.S.C.O. | |
8:45 AM | KRAS WT PDAC: Targets Galore | |
9:00 AM | Other Emerging Targets in PDAC | |
Pancreas Session II: Reimagining the Standard in Localized Pancreatic Cancer Moderator: Ryan M. Carr, M.D., Ph.D. | ||
9:20 AM | Next-Generation Trial Design in the Perioperative Management of Pancreatic Cancer | |
9:40 AM | The Role of PET in Staging and Response in Pancreatic Adenocarcinoma | |
10:00 AM | Interactive Q&A Session Presenters | |
10:15 AM | AM Break and Exhibits | |
Pancreas Session III: Advances in Neuroendocrine and Other Pancreatic Malignancies Moderator: Thor R. Halfdanarson, M.D. | ||
10:35 AM | Is Radiation Useful in Pancreatic Neuroendocrine Tumors? Krishan R. Jethwa, M.D., M.P.H. | |
10:50 AM | Surgical Management of Functioning and Non‑Functioning Pancreatic Neuroendocrine Tumors Alexandra Gangi, M.D. | |
11:10 AM | Neoadjuvant Therapy for PNET: CAP/TEM and Beyond | |
11:30 AM | De Novo PDAC vs Invasive-IPMN: Is There a Real Difference? Katherine Poruk, M.D. | |
11:50 AM | Interactive Q&A Session Presenters | |
Pancreas Session IV: Multidisciplinary Tumor Board Moderator: Katherin Poruk, M.D., and Thor R. Halfdanarson, M.D. | ||
12:05 PM | Localized PNET Panelists: Eileen M. O'Reilly, M.D., Bassel F. El-Reyes, M.D., Nilofer S. Azad, M.D., F.A.S.C.O., Ben George, M.B.B.S., M.D., Krishnan R. Jethwa, M.D., M.P.H., Alexandra Gangi, M.D., Mark J. Truty, M.D., M.S., and Daniel Adamo, M.D. | |
12:25 PM | High Risk Non-Metastatic PDAC Panelists: Eileen M. O'Reilly, M.D., Bassel F. El-Reyes, M.D., Nilofer S. Azad, M.D., F.A.S.C.O., Ben George, M.B.B.S., M.D., Krishnan R. Jethwa, M.D., M.P.H., Alexandra Gangi, M.D., Mark J. Truty, M.D., M.S., and Daniel Adamo, M.D. | |
12:45 PM | Recurrent/Metastatic PDAC/PNET Panelists: Eileen M. O'Reilly, M.D., Bassel F. El-Reyes, M.D., Nilofer S. Azad, M.D., F.A.S.C.O., Ben George, M.B.B.S., M.D., Krishnan R. Jethwa, M.D., M.P.H., Alexandra Gangi, M.D., Mark J. Truty, M.D., M.S., and Daniel Adamo, M.D. | |
1:05 PM | Interactive Q&A Session Presenters | |
1:20 PM | Closing Remarks and Adjourn | |
All travel and lodging expenses are the sole responsibility of the individual registrant.
A limited number of hotel rooms for this course will be available to book as part of a room block reserved for this course at a rate of $369 for Thursday November 12, Friday November 13 and Saturday November 14, 2026. All room reservations within the course room block must be made by Wednesday, September 16, 2026. Individual attendee’s reservations not canceled at least seventy-two (72) hours in advance of the confirmed arrival date will be subject to the cancellation charge equal to the first night’s room/suite rate and tax.
The Guest Room/Suite rates quoted above are exclusive of the daily resort fee and applicable state and local taxes room tax (“Clark County”) at the time of stay which is currently 13.38%, subject to change. A $55.00 daily resort fee plus the applicable state and local taxes. Room Tax is applied to each hotel room reservation and includes amenities.
For all registered guests, the resort fee includes: In-room Wi-Fi: four (4) devices per room at a standard 10Mb connection speed, access to the fitness center for two people, access to resort pools and sundecks, a dedicated concierge offering special dining access, spa reservations and golf tee times, unlimited local, domestic long distance (including Hawaii & Alaska) and toll-free calls, complimentary digital access to more than 5,000 newspapers and magazines from around the world, and Alexa in-room entertainment services and room controls.
Please note that there is a charge of $50.00 per room per night for double queen accommodations at Wynn for weekday; and $70.00 per room per night for weekends. A charge of $50 per night will be added for each guest over double occupancy.
Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Statement(s):
AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 12.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA
Mayo Clinic College of Medicine and Science has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 12.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
ANCC
Mayo Clinic College of Medicine and Science designates this activity for a maximum of 12.00 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Other Healthcare Professionals:
A record of attendance will be provided to all registrants for requesting credits in accordance with state nursing boards, specialty societies or other professional associations.
For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.
Available Credit
- 12.00 AAPA Category 1
- 12.00 ABS - Accredited CME
- 12.00 AMA PRA Category 1 Credit™
- 12.00 ANCC
- 12.00 Attendance
Sponsorship and Exhibit Opportunities
This course offers a unique opportunity for commercial companies to engage directly with healthcare providers and showcase their products and services through sponsorship and exhibit options. Space is limited and will be reserved upon receipt of a completed agreement.
To explore sponsorship and exhibit options, please review the Exhibit/Sponsorship Prospectus (PDF). If you are interested, please complete the Exhibit/Sponsorship Letter of Agreement. Please note: you will need to create a profile/account before accessing the form, if you do not already have one.
Please email Dorinda Johnson with questions.
To see the course fee, please log in or create an account
| Registration Fee(s) | |
|---|---|
| M.D., D.O., Ph.D. | $875 |
| Residents, Physician Assistants and Nurse Practitioners | $750 |
| Livestream | $675 |
Before registering, please update your profile.
To claim credit for livestream participation in this course, learners must view the content during the hours posted for the live activity. This course is not approved for on-demand delivery.
Commitment to Belonging and Inclusion
Mayo Clinic School of Continuous Professional Development (MCSCPD) strives to foster a learning environment in which all individuals are valued, allowing all to achieve their fullest potential.
Every effort will be made to accommodate dietary requirements; however, some requests may not be feasible based on venue kitchen capabilities. Attendees will be contacted in advance if a dietary restriction cannot be fulfilled.
The Mayo Clinic School of Continuous Professional Development strives for fully accessible learning experiences. If you anticipate any barriers while attending this course, please reach out to the course coordinator who will be in touch with all registrants. If you need disability-related accommodations, please contact the Office of Wellness and Academic Support – Disability Access Services at MCCMS.DS@mayo.edu.
Cancellation and Refund Policy
View Cancellation and Refund Policy
All requests must be submitted in writing using the Contact Us Form.
Any use of this site constitutes your agreement to the Terms and Conditions of Registration.